Guorun International Medical is expanding its network of international medical innovation projects and China-based partners, connecting overseas developers with opportunities in clinical collaboration, market access and distribution.

Recent coverage of Boao Lecheng by CCTV Finance’s Economic Half Hour has drawn attention to international healthcare innovation and its progression toward clinical use and commercialization in China. Against this backdrop, Guorun is developing collaborations across innovative pharmaceuticals and medical devices, with Boao Lecheng serving as a focal point for international engagement.

Connecting Global Medical Innovators in Boao Lecheng

Held from May 29 to 31, 2026, the global recruitment and launch conference for innovative pharmaceuticals and medical devices brought together more than 30 companies from 11 countries and regions. Participants included businesses from the United States, Israel, Germany, South Korea, Switzerland, Italy, Finland, Türkiye, Spain and Australia.

Conference backdrop in Boao Lecheng, May 29–31, 2026. The event brought together international medical innovators and China-based partners.

Representatives at a signing ceremony during the conference in Boao Lecheng.

More than 40 innovation projects were showcased, spanning bone regeneration, autologous adipose tissue and stromal vascular fraction (SVF) preparation, cardiovascular anti-inflammatory therapies, men’s health, ophthalmology, kidney disease and medical artificial intelligence.

Representatives of healthcare institutions, investment organizations and distribution businesses discussed international product introduction, special access for eligible products in Lecheng, localization and registration, and wider market development in China. The discussions also advanced a number of potential collaborations.

For Guorun, the conference provided an opportunity to connect overseas developers with clinical and commercial partners in China. It formed part of the company’s continuing work to expand its international project network and move suitable collaborations forward.

Healthcare and industry participants attending the conference in Boao Lecheng.

Expanding a Portfolio Across Medical Specialties

Beyond the May conference, Guorun is continuing product collaborations and project development across men’s health, orthopedics, ophthalmology, hair restoration and kidney care. Selected projects include the following technologies.

Vertica® radiofrequency device

A men’s health technology using radiofrequency energy for erectile dysfunction. Guorun is exploring opportunities for its application and market development in China.

Supintro™ intra-articular gel implant

A sterile, absorbable, hyaluronic acid-containing intra-articular gel implant. Guorun is exploring its potential clinical and commercial role within orthopedic care in China.

eyeWatch adjustable glaucoma drainage implant

An adjustable drainage implant for glaucoma, including cases where medical and/or conventional surgical treatment has failed.

Medicap® artificial hair implantation system

A system for artificial hair implantation, with associated post-procedure care forming part of the broader hair restoration pathway.

Nephrospec™ acoustic therapy device

A non-invasive technology based on electrohydraulic acoustic therapy (eHAT), being explored in the context of chronic kidney disease and hypertension. Guorun is investigating opportunities for its development in China.

Selected products in Guorun’s international project portfolio. Product packaging and manufacturer branding are reproduced from the original material.

These projects illustrate the breadth of Guorun’s international collaborations. Product cooperation and project development do not, on their own, establish approval for general sale or clinical use in China; each project follows the applicable access and regulatory pathway.

Building a Pathway from Project Selection to Market Development

Introducing a product to China is one stage in a longer development process. Clinical needs, evidence generation, regulatory requirements, distribution and local industrial partnerships all influence how a project can progress.

Guorun is developing a cooperation pathway that connects project screening and market entry with clinical collaboration, registration planning and commercial development. Its aim is to help each suitable innovation identify a practical route for the China market.

Guorun International Medical’s cooperation pathway from global project screening to market and distribution development.

The approach brings together manufacturers, healthcare institutions, clinical experts, registration resources and distribution partners. The relevant steps depend on the product, its evidence base and applicable requirements; they are assessed for each project.

Seeking Distributors and Channel Partners in China

As its international portfolio develops, Guorun is expanding its network of domestic distributors and channel partners. Local knowledge and professional support are needed to connect clinical awareness with regional market development and sustained operations.

Guorun welcomes discussions with prospective partners that offer:

· Professional medical device sales teams with knowledge of regional healthcare markets and experience in product promotion.

· Established relationships with healthcare institutions and clinical experts.

· Regional distribution networks capable of supporting consistent market coverage.

· Market development capabilities, including product education, promotion and ongoing operations.

· Healthcare industry experience and a commitment to long-term collaboration.

For China-based partners, Guorun aims to provide access to international innovation opportunities and the prospect of cooperation extending beyond a single product. For overseas developers, the network is intended to support engagement with relevant clinical, commercial and industrial resources in China.